ABBV/ENTA’s 54% share of worldwide 4Q18 HCV sales (from ABBV or GILD) will hold roughly constant in 2019, according to the 2019 HCV sales guidance given by ABBV ($3.3B) and GILD ($2.7-2.9B).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.